Epigenetically Active Supplements and Sports Injuries: What Does Science Really Say?

A recent narrative review titled "Epigenetically Active Supplements and the Risk of Sports Injuries: Narrative Review from Molecular Mechanisms to Practical Implications" by Leońska-Duniec A, published in the journal Nutrients, sheds exciting light on the role of epigenetically active supplements in preventing sports injuries. But what's really behind the promises? I'll take you on a detective journey through the study, expose its weaknesses, and translate the findings into your daily life. Source

1. Cui Bono? The Trail of Money and Interests

First, the uncomfortable question: Who benefits from this review? The study itself provides no explicit indications of funding by the supplement industry, and the author Leońska-Duniec A appears to be primarily academically motivated. Nevertheless, a critical eye remains important, as narrative reviews are often susceptible to selective presentations that could promote certain products or concepts. The supplement industry has a multi-billion dollar interest in using epigenetic effects as a selling point. Without direct evidence of conflicts of interest, this remains a hypothesis, but I urge you to always question who might benefit from such narratives.

2. The Methodological Ordeal: The Foundation of the Study

Leońska-Duniec's work is not a classic experiment, but a narrative review. This means it is a summarizing analysis of existing literature, without its own standardized study design with control groups or defined sample sizes. The author collected studies on epigenetically active substances such as omega-3 fatty acids, vitamin D, and polyphenols (e.g., resveratrol) and investigated their influence on gene expression and injury risks in a sports context. The review considers molecular mechanisms (e.g., DNA methylation, histone modifications) and attempts to link these with clinical data.

Since it is a narrative review, there is no uniform study population or measurement methods – the author relies on a wide range of studies, from cell cultures to animal studies to human observational studies. This carries a risk: the comparability of results is limited. Neither a duration of interventions nor a uniform control group is defined, as the review is based on secondary data. A selection bias is obvious here – were only studies showing positive effects selected? The author does not specify systematic criteria for study selection, which weakens the evidentiary value. Imagine a narrative review as a colorful patchwork quilt: It can look beautiful, but the individual s